New shot could slash Sky-High cholesterol in rare genetic disease
NCT ID NCT06712771
First seen May 13, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study tests a new medicine called VSA003 in 46 Chinese teenagers and adults with homozygous familial hypercholesterolemia (HoFH), a genetic condition causing extremely high cholesterol and early heart disease. VSA003 uses RNAi technology to lower a protein (ANGPTL3) that controls fat levels, aiming to reduce bad cholesterol and triglycerides. Participants must follow a low-fat diet and stable cholesterol meds; the main goal is to see how much LDL cholesterol drops after 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.